Why the study?
Does statin treatment prevent the decline of renal function in dyslipidaemic patients with coronary heart disease?
Does statin treatment prevent the decline of renal function in dyslipidaemic patients with coronary heart disease?
Statin therapy prevents the decline of and improves renal function (CrCl) over three years in dyslipidemic patients with CHD.
Supports statin use for renal preservation in dyslipidemic CHD patients; confirms renoprotection in this RCT.
In untreated dyslipidaemic patients with CHD and normal renal function at baseline, CrCl declines over a period of three years. Statin treatment prevents this decline and significantly improves renal function, potentially offsetting an additional factor associated with CHD risk.
No takes yet. Share an insight, caveat, or question.
Athyros et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: